Host metabolism balances microbial regulation of bile acid signalling
- PMID: 39779854
- PMCID: PMC11886927
- DOI: 10.1038/s41586-024-08379-9
Host metabolism balances microbial regulation of bile acid signalling
Abstract
Metabolites derived from the intestinal microbiota, including bile acids (BA), extensively modulate vertebrate physiology, including development1, metabolism2-4, immune responses5-7 and cognitive function8. However, to what extent host responses balance the physiological effects of microbiota-derived metabolites remains unclear9,10. Here, using untargeted metabolomics of mouse tissues, we identified a family of BA-methylcysteamine (BA-MCY) conjugates that are abundant in the intestine and dependent on vanin 1 (VNN1), a pantetheinase highly expressed in intestinal tissues. This host-dependent MCY conjugation inverts BA function in the hepatobiliary system. Whereas microbiota-derived free BAs function as agonists of the farnesoid X receptor (FXR) and negatively regulate BA production, BA-MCYs act as potent antagonists of FXR and promote expression of BA biosynthesis genes in vivo. Supplementation with stable-isotope-labelled BA-MCY increased BA production in an FXR-dependent manner, and BA-MCY supplementation in a mouse model of hypercholesteraemia decreased lipid accumulation in the liver, consistent with BA-MCYs acting as intestinal FXR antagonists. The levels of BA-MCY were reduced in microbiota-deficient mice and restored by transplantation of human faecal microbiota. Dietary intervention with inulin fibre further increased levels of both free BAs and BA-MCY levels, indicating that BA-MCY production by the host is regulated by levels of microbiota-derived free BAs. We further show that diverse BA-MCYs are also present in human serum. Together, our results indicate that BA-MCY conjugation by the host balances host-dependent and microbiota-dependent metabolic pathways that regulate FXR-dependent physiology.
© 2025. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: D.A. has contributed to scientific advisory boards at Pfizer, Takeda, Nemagene and the Kenneth Rainin Foundation. F.C.S. is a cofounder of Ascribe Bioscience and Holoclara Inc., and a member of the scientific advisory board of Hexagon Bio. The other authors declare no competing interests.
References
-
- Robertson RC, Manges AR, Finlay BB & Prendergast AJ The human microbiome and child growth — first 1000 days and beyond. Trends Microbiol. 27, 131–147 (2019). - PubMed
-
- Fuchs CD & Trauner M Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat. Rev. Gastroenterol. Hepatol. 19, 432–450 (2022). - PubMed
-
- Thomas C, Pellicciari R, Pruzanski M, Auwerx J & Schoonjans K Targeting bile-acid signalling for metabolic diseases. Nat. Rev. Drug Discov. 7, 678–693 (2008). - PubMed
-
- Wahlstrom A, Sayin SI, Marschall HU & Backhed F Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41–50 (2016). - PubMed
MeSH terms
Substances
Grants and funding
- R01 DK135816/DK/NIDDK NIH HHS/United States
- R01 AR070116/AR/NIAMS NIH HHS/United States
- R01 AI095466/AI/NIAID NIH HHS/United States
- K08 MH130773/MH/NIMH NIH HHS/United States
- DP2 HD101401/HD/NICHD NIH HHS/United States
- R01 DK132244/DK/NIDDK NIH HHS/United States
- R01 DK126871/DK/NIDDK NIH HHS/United States
- K99 AI173660/AI/NIAID NIH HHS/United States
- R01 AI151599/AI/NIAID NIH HHS/United States
- R01 DK116187/DK/NIDDK NIH HHS/United States
- R01 AI172027/AI/NIAID NIH HHS/United States
- R01 DK140854/DK/NIDDK NIH HHS/United States
- R35 GM131877/GM/NIGMS NIH HHS/United States
- U01 AI095608/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous
